Publications by authors named "S Jilg"
Article Synopsis
- Momelotinib, a newly approved JAK1/2 inhibitor, shows promise in treating myelofibrosis (MF) patients, particularly those with anemia, improving hemoglobin and platelet levels over a median treatment duration of 12 weeks.
- In a study of 60 MF patients, 39% of transfusion-dependent individuals experienced reduced transfusion needs, with 21% achieving transfusion independence in about 4 weeks.
- While momelotinib is effective, it also presented safety concerns, with 17% of patients experiencing creatinine increases, and some patients discontinued treatment due to side effects or worsening symptoms.
Thromboembolic events are common in patients with essential thrombocythemia (ET). However, the pathophysiological mechanisms underlying the increased thrombotic risk remain to be determined. Here, we perform the first phenotypical characterization of platelet expression using single-cell mass cytometry in six ET patients and six age- and sex-matched healthy individuals.
View Article and Find Full Text PDFBackground: Mutations in cKIT or PDGFRA are found in up to 90% of patients with gastrointestinal stromal tumors (GISTs). Previously, we described the design, validation, and clinical performance of a digital droplet (dd)PCR assay panel for the detection of imatinib-sensitive cKIT and PDFGRA mutations in circulating tumor (ct)DNA. In this study, we developed and validated a set of ddPCR assays for the detection of cKIT mutations mediating resistance to cKIT kinase inhibitors in ctDNA.
View Article and Find Full Text PDF